Our guideline working group has reviewed latest evidence and recommends therapeutic anticoagulation (instead of prophylactic) for mild and moderate COVID-19. This is based on review of latest evidence from 3 international trials, demonstrating marked benefit (net benefit in terms of organ-support free days, irrespective of D-dimer levels). No benefit (and possible harm) for severe COVID-19. Endorsed by MUHC P&T committee!
top of page
Search
Recent Posts
See AllThe ASP committee is happy to give you an early Christmas gift! We published the guidelines on management and treatment of Staphylococcus aureus bacteremia. The diagnostic and antibiotic choice are di
400
ASP committee developed a post-exposure prophylaxis (HIV, hepB & hepC) guidelines in collaboration with the CVIS team. It is available on our website! Francois Bourdeau ASP MUHC coordinator
210
The ASP committee updated the COVID guidelines. You will find the following change: -Removal of the pre-exposure prophylaxis guidelines since monoclonal antibodies are no longer easly available. -Clar
450
bottom of page